BEAM's IND for BEAM-302 in Genetic Disorder Study Gets FDA Clearance

Beam Therapeutics Inc. (BEAM) announced that the FDA has cleared the investigational new drug (IND) application to begin clinical studies on its pipeline candidate, BEAM-302, for the treatment of alpha-1 antitrypsin deficiency (AATD) in the United States.BEAM-302 is a liver-targeting lipid-nanoparticle (LNP) formulation of base editing reagents designed to correct the disease-causing PiZ mutation.AATD is an inherited genetic disorder that can cause early onset of emphysema and liver disease. Currently, ther ...